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ABSTRACT
Acute coronary syndromes represent the most severe consequences of atherosclerosis, most 
often triggered by the rupture of a coronary plaque, which, for various reasons, has become 
unstable. In many cases, these rupture-prone vulnerable plaques are difficult to diagnose, 
because they do not always cause significant obstruction noticeable by coronary angiogra-
phy. Therefore, new methods and tools for the identification of vulnerable plaques have been 
proposed, many of which are currently under study. Various biomarkers have been suggested 
as predictors of a vulnerable plaque, as well as indicators of an increased inflammatory sta-
tus associated with higher patient susceptibility for plaque rupture. Integration of such bio-
markers into multiple biomarker platforms has been suggested to identify superior diagnos-
tic algorithms for the early detection of the high-risk condition associated with an unstable 
plaque. The aim of this review is to summarize recent research related to biomarkers used for 
the early detection of vulnerable plaques and vulnerable patients.
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BACkgROuND
Cardiovascular diseases (CVD) are amongst the leading 
causes of mortality and morbidity worldwide.1 Accord-
ing to the World Health Organization (WHO), 17.5 mil-
lion people died from CVD in 2012, representing 31% of 
all global deaths. The majority of CV deaths are caused 
by the progression of atherosclerosis, resulting in acute 
coronary syndromes or stroke. WHO also estimates that 
7.4 million deaths occurred due to coronary heart disease 
and 6.7 million were caused by stroke, and it is currently 
predicted that 23.6 million people will die annually by 
2030 due to CVD.1
Acute myocardial infarction is a disease with a strong 
effect on patients' health and quality of life. If not treat-
ed promptly by appropriate reperfusion therapy, severe 
complications, such as heart failure, arrhythmia, throm-
boembolism or even death, may occur. Myocardial infarc-
tion (MI) can have a substantial negative impact on the 
DOI: 10.1515/jce-2016-0017
107Journal of Cardiovascular Emergencies 2016;2(3):106-113
social, economic and psychological status of the patients, 
who prior to the MI were active.2 If the patient is treated 
in time, and a coronary stent is implanted at the site of 
the infarction, there is a lower risk of complications. How-
ever, limitations in exercise capacity, with consequent 
deterioration of the quality of life will remain. Therefore, 
effective preventive strategies aimed at moderating the 
progression of the “vulnerable patients” towards devel-
oping an acute myocardial infarction could lead not only 
to a significant reducing in healthcare costs, but also to 
a substantial improvement in the quality of life in these 
patients.3
Acute coronary syndromes (ACS) represent the most 
severe consequences of atherosclerosis, most often being 
triggered by the rupture of a coronary plaque, which, for 
different reasons, becomes unstable. Plaque rupture has 
been identified as the pathophysiologic substrate in more 
than 75% of all fatal heart attacks.4 However, it has been 
proved that 25–40% of STEMI are produced by plaques 
with an intact fibrous cap. These types of plaques usually 
present with lower degrees of lipid reach core, and less 
frequently have a thin-capped fibroatheroma.5 One ma-
jor question is why a coronary plaque suddenly becomes 
unstable and ruptures. Timely identification of rupture-
prone plaques could lead to the appropriate initiation of 
suitable therapeutic measures. The ability to detect the 
risk of having a myocardial infarction, and to contribute 
to the proper treatment of these lesions before plaque 
rupture and consequent myocardial infarction, would 
assist in preventing plaque rupture and the subsequent 
acute coronary event.6 In many cases, vulnerable plaques 
are difficult to diagnose, because they do not always 
cause significant obstruction as seen by coronary angi-
ography.4
Standard diagnostic tools, such as conventional coro-
nary angiography, focus more on luminal narrowing than 
on plaque characteristics and are unable to estimate the 
vulnerability of a coronary plaque, and therefore cannot 
predict if a plaque is prone to rupture with the subsequent 
risk of an acute coronary event.4
Various biomarkers have been proposed to character-
ize vulnerable plaques and to gauge the increased in-
flammatory status associated with patient vulnerability. 
Integration of such biomarkers into multiple biomarker 
platforms has been suggested with the aim of achieving 
superior diagnostic algorithms for the early detection of 
the high-risk conditions. In this review, the most recent 
progress relating to the use of biomarkers for the early 
detection of vulnerable plaques and vulnerable patient, 
is summarized.
VuLNERABLE PLAquE AND 
VuLNERABLE PATIENT
The concept of the vulnerable patient has been introduced 
to describe a status characterized by an increased suscep-
tibility to the localized action of factors destabilizing the 
plaque, and exposing the person to a higher risk of plaque 
rupture. Nowadays it is considered that an acute coronary 
event is the result of an interaction between plaque vul-
nerability and patient vulnerability.7 Therefore, the cur-
rent approach for predicting the risk of an acute coronary 
event is based on the identification of both vulnerable cor-
onary plaques and the identification of biomarkers char-
acterizing the so-called “vulnerable patient”.
Recently, the concept of plaque sealing has been in-
troduced as a new therapeutic approach consisting of the 
implantation of a bio-absorbable scaffold at the site of a 
vulnerable plaque to prevent plaque rupture.8 It is well-
known that a large number of vulnerable coronary plaques 
do not result in any significant stenosis, making the deci-
sion to stent or not, very difficult in clinical practice.9 Cur-
rently, there is no consensus either when this technique 
should be employed in the treatment of unstable coronary 
plaques, or the role of different biomarkers as indicators 
of a specific therapeutic strategy.
SERum BIOmARkERS CHARACTERIzINg 
THE VuLNERABLE PATIENT
Serum biomarkers expressing an increased inflammatory 
status or disease severity, such as hsC-reactive protein, 
cardiac enzymes – troponin (Tn) and its highly sensitive 
form (hsTn), myoglobin, C-reactive protein (CRP) and 
its highly sensitive form (hsCRP), brain natriuretic pep-
tide and NT-proBNP, galectine-3, neutrophil gelatinase-
associated lipocalin, myeloperoxidase (MPO), cytokines 
(Growth differentiation factor 15) or interleukines (Soluble 
ST2), have been traditionally associated with an increased 
risk of an acute coronary event. As such, their detection 
could play an important prognostic role, though this role 
is still under investigation. Other novel serum biomarkers 
that are involved in the vulnerabilization process of the 
coronary atheromatous plaque include the matrix metal-
loproteinases (MMPs), the oxidized LDL cholesterol, apo-
lipoprotein B, as well as the homocysteine levels.10–14
Micro-RNAs are RNAs synthesized in the nucleus that 
regulate gene expression, and play a significant role in 
ischemic cardiovascular diseases. Recently it has been 
proposed that they can serve as biomarkers to monitor 
progression after an acute myocardial infarction, heart 
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failure and coronary artery disease, as miRNA disease-
specific signatures have been identified in a variety of CV 
diseases. For instance, miR-1, miR-133a, miR-133b, miR-
208a and miR-499 have been demonstrated to be asso-
ciated with acute myocardial infarction.15 However, the 
exact panel of microRNA specific for vulnerable plaque 
has not been identified so far, and it would be interesting 
to elucidate if these miRNA reflect the vulnerability of a 
plaque or the vulnerability of a patient.
LOCALLY RELEASED BIOmARkERS AT THE 
SITE Of THE VuLNERABLE PLAquE
Impaired function of the coronary endothelium leads to 
local release into the coronary circulation of inflammatory 
or pro-thrombotic biomarkers.16 So far, most biomarker 
studies have focused on circulating biomarkers released 
from plaques throughout the entire circulation, not just 
those locally sampled within the coronary arteries. The 
association between the various locally released biomark-
ers expressing inflammation, endothelial dysfunction, 
and the risk for plaque rupture has not been elucidated 
so far.17 Likewise, the role of different biomarkers derived 
from the coronary circulation, as an expression of in-
creased inflammation associated with vulnerable plaques, 
has not been clearly demonstrated.18 Currently, locally 
released biomarkers at the site of the vulnerable plaque, 
expressing inflammation and endothelial dysfunction, can 
be determined using liquid biopsy techniques.19 This bi-
opsy system was developed recently in order to provide a 
better indication of the risk associated with increased lev-
els of biomarkers collected along an atheromatous plaque, 
based on the calculation of the biomarker gradient be-
tween the region located upstream and downstream of the 
diseased tissue. The ongoing clinical trial “Study to Detect 
Biomarker Gradients in Coronary Arteries Using the Liquid 
Biopsy System (CS1)” will investigate this new procedure, 
aiming to enroll 70 patients with coronary artery disease 
undergoing routine percutaneous coronary intervention 
(PCI). The study will test the feasibility of the new liquid 
biopsy system device for the detection of local biomarkers 
released by diseased coronary arteries, and will also assess 
the link between these locally released biomarkers and the 
cardiovascular risk of the patient. 
ImAgINg-DERIVED BIOmARkERS 
CHARACTERIzINg VuLNERABLE PLAquE
Despite recent advances in the characterization of multiple 
imaging biomarkers associated with plaque vulnerability, 
there is no clear consensus on the predictive value of these 
biomarkers for predicting an acute coronary event.20
A vulnerable plaque is usually characterized by a large 
necrotic core, a thin fibrous cap with macrophage infil-
tration within the cap, a large lipid pool, and the pres-
ence of several specific signs such as positive remodel-
ing, irregular calcifications, and low attenuation at cardiac 
computed tomography.4,21 When these characteristics are 
present, the fibrous cap may rupture, and the lipid core, 
which is thrombogenic, is exposed to the blood flow, in-
ducing thrombus formation and causing an acute coro-
nary syndrome.22,23 At the same time, new imaging bio-
markers such as the epicardial fat thickness (EFT) have 
been demonstrated to be associated with coronary artery 
disease. However the association of EFT with vulnerable 
plaques or with patient vulnerability is still unclear, and 
controversies still exist regarding the role of several char-
acteristics of EFT such as volume or spatial distribution 
around coronary arteries, in predicting associated cardio-
vascular risk.24–27
The morphological characteristics associated with 
unstable plaques are evaluated by three main imaging 
methods: Coronary Computed Tomography Angiography 
(CCTA), Intravascular ultrasound with virtual histology 
(VH-IVUS), and Optical Coherence Tomography (OCT). 
The most common image-derived biomarkers associated 
with plaque vulnerability, as identified by leading imaging 
technologies, are summarized in Table 1.
Different studies have suggested an association between 
various parameters characterizing vulnerable plaques, as 
identified by one of the three imaging techniques, and 
development of acute coronary syndromes.28,29 However, 
these studies reported qualitative data related only to one 
imaging method, without taking into consideration the 
global picture of the vulnerable plaque. This could pos-
sibly be better characterized by the summation of all the 
information obtained by these techniques.24 
a) Coronary Computed Tomography Angiography for 
the assessment of vulnerable plaques. CCTA is a nonin-
vasive technique able to identify specific parameters as-
sociated with plaque vulnerability, such as spotty calcifi-
cations, active remodeling, and burden with a low-density 
plaque. Available software makes it possible to use this 
technique for quantitative analysis of plaque components 
based on different CT attenuations within the plaque.30
Motoyama et al. found that the presence of three mark-
ers of instability in the same plaque, spotty calcification, 
active remodeling and low-density atheroma, identified by 
cardiac computed tomography, were associated with the 
development of an acute coronary syndrome at two years.31
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Pal Maurovich-Horvat et al. described the presence of 
a ring-like attenuation pattern, also known as the nap-
kin-ring sign, of the coronary atherosclerotic vulnerable 
plaques, showed in coronary computed tomography angi-
ography (CCTA).32 Napkin-ring sign has been identified as 
a characteristic feature of the vulnerable plaque, consist-
ing in the presence of a low CT attenuation in the center 
of the plaque close to the lumen, surrounded by a rim area 
of a high attenuation. The specificity of this sign to iden-
tify unstable plaques was 98.9% (95% CI: 97.6-100%).33 
In this study, investigating twenty-one coronary arteries 
from seven donor hearts and correlating the histologi-
cal features with CCTA appearances, the presence of the 
napkin-ring sign was a strong predictor for advanced cor-
onary lesions. The study emphasized the ability of CCTA 
to recognize advanced atherosclerotic lesions associated 
with high vulnerability and increased probability for ad-
verse cardiovascular events.32
In a previous study, it was shown that unstable plaques 
are characterized by larger volumes of low-density lipid 
cores, and a critical volume of 0.2 ml very low CT density 
plaque (<30 HU) was associated with the development of 
an acute coronary syndrome by Benedek et al.34
New CT-based imaging biomarkers, such as epicardial 
fat thickness, have been proposed as markers of coronary 
artery disease and the severity of plaque instability. A re-
cent publication described the role of EFT in characteriz-
ing the severity of coronary artery disease.24 However, the 
role of this EFT as a biomarker describing patient vulner-
ability and expressing an increased inflammatory status 
in patients with vulnerable plaques is yet to be clarified. At 
the same time, several new hypotheses regarding the role 
of new CT-based biomarkers have been proposed and are 
currently under investigation, such as the role of trans-
stenotic contrast density gradient in predicting the plaque 
severity and vulnerability.34
b) Optical coherence tomography (OCT) is an intra-
coronary imaging technology which provides accurate 
data related to plaque morphology and quantification, and 
is considered to be the gold standard for measurements of 
the fibrous cap thickness and visualization of intracoro-
nary thrombus or intimal rupture. The most frequently 
used OCT-derived biomarker for the assessment of plaque 
vulnerability is the thickness of the fibrous cap, and OCT 
studies have identified the presence of a thin fibrous cap, 
less than 65 microns, as a high-risk indicator of plaque 
rupture.28 New OCT-based biomarkers characterizing vul-
nerable plaques have been proposed, such as the accumu-
lation of macrophages in the fibrous cap, and these can be 
detected easily with OCT.28
Several OCT studies have demonstrated the presence of 
lipid-rich plaques in 100% of ruptured plaques. However, 
this biomarker was present in only 43% of plaques with an 
intact fibroatheroma cap.5
In an OCT substudy of the TOTAL trial (ThrOmbecTomy 
versus PCI Alone), the lipid content was lower in culprit 
plaques with intact fibrous plaques as compared to rup-
tured plaques. However, a significant lipid core was pres-
ent in all the culprit plaques, while the thickness of the 
fibrous cap was significantly lower in ruptured plaques as 
compared to intact cap plaques (62.05 ± 9.13 microM vs. 
91.03 ± 16.97 microM, p <0.0001).5
c) VH-IVUS can combine intracoronary imaging data 
with a color coded representation of plaque components, 
classifying them as fibrous, calcific, lipid reach or necrotic 
core, at the same time quantifying plaque components and 
volumes.35 However, it does not provide a clear assessment 
of the fibrous cap thickness or intracoronary thrombus.36 
TABLE 1. Image-derived biomarkers associated with plaque vulnerability, as identified by 
main imaging technologies
Image-derived biomarkers for plaque  
vulnerability 
CT VH-IVUS OCT NIRF
Necrotic core NO YES NO NO
Positive remodelling YES YES NO NO
Spotty calcification YES YES NO NO
Napkin-ring sign YES NO NO NO
Lipid-reach plaque YES YES YES YES
Plaque erosion NO NO YES NO
Thin cap fibroatheroma NO NO YES NO
Thrombus NO NO YES NO
Macrophage content NO NO YES NO
CCTA – Coronary Computed Tomography Angiography; VH-IVUS – Virtual histology-intravascular ultrasound; 
OCT – optical coherence tomography; NIRS – near infrared spectroscopy
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IVUS studies identified the presence of a large necrotic core 
as a marker of vulnerability.37 A previous study described 
the association between a necrotic core determined by VH-
IVUS and the low-density core within the unstable coro-
nary plaque, demonstrating that the dark spots associated 
with the napkin-ring sign shown by CT, represent in fact 
the necrotic core of the vulnerable plaque.38
d) Near infrared spectroscopy is a technique used for 
evaluation of the lipid content of the atheromatous plaque, 
as a direct indicator of its vulnerability. It provides the 
advantage of precise identification of lipid-rich plaques, 
providing a chemogram of the arterial wall.29
Serial Radiofrequency-IVUS and Near Infrared Spectros-
copy proved to be efficient techniques for monitoring the 
size and regression of the necrotic core, as demonstrated in 
the Integrated Biomarker and Imaging Study 3 (IBIS-3).39
NEw ADVANCES IN COmPLEx BIOmARkER 
DETECTION IN VuLNERABLE PLAquES
Coronary shear stress is a new biomarker characteriz-
ing coronary circulation. Determination of coronary shear 
stress has become possible due to advanced techniques 
of computational fluid dynamics, which are based on the 
computerized processing of CT or OCT derived image se-
quences.26,40 It has been recognized that unstable plaques 
develop particularly in sites with a low shear stress, and 
that shear stress directly relates to the risk of develop-
ing an acute coronary event.41 It is also well-known that 
the local impaired function of the coronary endothelium, 
caused by the presence of a large low-density core, may 
indicate plaque vulnerability, and that shear stress is a 
direct indicator of local impaired function of the coro-
nary endothelium.42 Yi Wang et al. stated that a high shear 
stress is associated with vulnerable plaque formation and 
also with vascular remodeling.43 High shear stress might 
play a role in the expression of the vascular endothelial 
growth factor, which induces angiogenesis and also cre-
ates lesions in the vascular barrier function.44 However, it 
is still unclear if high shear stress is directly related to the 
rupture of a vulnerable plaque.
Noninvasive determination of coronary flow reserve 
using CT image datasets and computational flow dynam-
ics has been shown to represent an alternative to invasive 
FFR in determining the functional significance of a coro-
nary plaque.45
The noninvasive measurement of FFR combines ana-
tomical assessment of lesion severity provided by CT with 
the hemodynamic assessment of functional significance, 
provided by computer modeling.46 In a study which com-
bined the diagnostic value of CT imaging of coronary 
plaques with noninvasive FFR for the identification of le-
sions causing ischemia, the CT markers of plaque vulner-
ability such as active remodeling, spotty calcification and 
low attenuation plaque were associated with ischemia, 
and improved the identification and reclassification of 
coronary lesions causing ischemia, over stenosis degree 
evaluated with CT plus FFR, measured using computa-
tional fluid dynamics applied to CT images.47 However, the 
application of this technique in generating image-based 
biomarkers characterizing vulnerable plaques is still un-
der investigation. In a recent study, Ahmadi A et al. stated 
that abnormal FFR could translate lesions that consist of 
a large necrotic core, with severe ischemia.48 Also, they 
concluded that FFR represents a dependable technique, 
able to identify a vulnerable coronary plaque independent 
of luminal stenosis.48
Molecular imaging of vulnerable plaque: molecular 
imaging is a promising field, and many imaging-based 
biomarkers have been proposed as identifiers of vulner-
able plaques. For instance, 18F-labelled nanobodies tar-
geting vascular adhesion molecule-1 were used for PET/
CT imaging of atherosclerotic plaques with a high degree 
of inflammation inside the plaque, providing relevant in-
formation to characterize atherosclerotic plaque inflam-
mation and vulnerability.49
Nanoparticle-based imaging of vulnerable plaque: 
when a plaque ruptures, the fibrous cap is injured, and 
the lipid core, which is thrombogenic, is exposed to cir-
culation, inducing thrombus formation.50 Vulnerable, 
rupture-prone plaques are often relatively large, have a 
thin fibrous cap, are associated with expansive remodel-
ing, and have a large number of inflammatory cells in-
cluding macrophage-derived foam cells.51,52 Atheroma-
oriented nanotechnologies have been suggested for the 
visualization of macrophage accumulations within vul-
nerable plaques, and may represent a marker of plaque 
instability.53 Specific nanoparticles can be used as con-
trast agents for ultrasound, computed tomography and 
MRI to detect macrophages, as the macrophage content 
is directly associated with the degree of inflammation 
in the vulnerable plaque.54 These macrophage-targeting 
nanoparticles could be constructed from various materi-
als, such as dielectric silica core covered by a thin metal-
lic, gold or silver shell, and characterize a novel nanopar-
ticle-based atherosclerotic plaques identification agent, 
detectable by CT, and which is phagocytized by macro-
phages and monocytes.55,56 Such a contrast agent is thus 
able to differentiate between stable and unstable vulner-
able plaques.57,58
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CONCLuSION
The development of novel assays and imaging techniques 
has resulted in the advancement of biomarker technol-
ogy, which allows the detection and classification of both 
vulnerable plaques and vulnerable patients. However, a 
complex risk-assessment model based on integration of 
imaging-derived biomarkers and different patient-spe-
cific information related to systemic biomarkers, has yet 
to be perfected. 
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